Pain Burden in Children and Adolescents With Cerebral Palsy
NCT04219020
Recruiting
Pain in children and adolescents with cerebral palsy (CP) is a significant health challenge that so far has received too little attention. We lack knowledge on how pain is experienced, its consequences and of perceived support in managing pain. The overarching aim of the CPPain-program is to reduce pain experience, pain interference (e.g. pain burden) in children and adolescents living with CP. CPPain has a prospective cohort comparative design and will include before- and after measurements and... Read More
Gender:
All
Ages:
Between 0 years and 67 years
Trial Updated:
11/30/2023
Locations: Gillette Children's Speciality Healthcare, Saint Paul, Minnesota
Conditions: Cerebral Palsy
Register for Updates
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262
Recruiting
This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high pr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Register for Updates
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT04164082
Recruiting
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's im... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Fairview Ridges Hospital, Burnsville, Minnesota
Conditions: Bladder Urothelial Carcinoma In Situ, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Invasive Bladder Mixed Carcinoma
Register for Updates
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04069273
Recruiting
Cohort 1 [CLOSED] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Mayo Clinic- Minnesota, Rochester, Minnesota
Conditions: Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Register for Updates
TRC-PAD Program: In-Clinic Trial-Ready Cohort
NCT04004767
Recruiting
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstud... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
11/30/2023
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
Register for Updates
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447
Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Glioblastoma
Register for Updates
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
NCT03942653
Recruiting
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Salivary Gland Carcinoma
Register for Updates
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03930953
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota
Conditions: Lymphoma, Non-Hodgkin
Register for Updates
Pan Tumor Nivolumab Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab in participants on treatment and in follow up.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Allina Health, Minneapolis, Minnesota
Conditions: Cancer
Register for Updates
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
NCT02997228
Recruiting
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
NCT02854033
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
11/30/2023
Locations: Mayo Clinic, Rochester, Rochester, Minnesota
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Register for Updates
The National Myelodysplastic Syndromes (MDS) Study
NCT02775383
Recruiting
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Myelodysplastic Syndromes (MDS)
Register for Updates